Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2021 Financial Results on March 17, 2022
27 January 2022 - 11:30PM
Business Wire
Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a
maker of medical devices and supplies and the developer of Helium
Plasma Technology, marketed and sold as Renuvion® in the cosmetic
surgery market and J-Plasma® in the hospital surgical market, today
announced that financial results for the fourth quarter and fiscal
year 2021 will be released before the market opens on Thursday,
March 17th.
Management will host a conference call at 8:00 a.m. Eastern Time
on March 17th to discuss the results of the quarter and fiscal
year, and to host a question and answer session. To listen to the
call by phone, interested parties may dial 877-407-8289 (or
201-689-8341 for international callers) and provide access code
13726730. Participants should ask for the Apyx Medical Corporation
Call. A live webcast of the call will be accessible via the
Investor Relations section of the Company’s website and at:
https://themediaframe.com/mediaframe/webcast.html?webcastid=rZxrcAMy.
A telephonic replay will be available approximately two hours
after the end of the call through March 31, 2022. The replay can be
accessed by dialing 877-660-6853 for U.S. callers or 201-612-7415
for international callers and using the replay access code:
13726730. The webcast will be archived on the Investor Relations
section of the Company’s website.
About Apyx Medical
Corporation:
Apyx Medical Corporation is an advanced energy technology
company with a passion for elevating people’s lives through
innovative products in the cosmetic and surgical markets. Known for
its innovative Helium Plasma Technology, Apyx is solely focused on
bringing transformative solutions to the physicians and patients it
serves. The Company’s Helium Plasma Technology is marketed and sold
as Renuvion in the cosmetic surgery market and J-Plasma in the
hospital surgical market. Renuvion offers surgeons and physicians a
unique ability to provide controlled heat to the tissue to achieve
their desired results. The J-Plasma system allows surgeons to
operate with a high level of precision and virtually eliminating
unintended tissue trauma. The Company also leverages its deep
expertise and decades of experience in unique waveforms through
original equipment manufacturing (OEM) agreements with other
medical device manufacturers. For further information about the
Company and its products, please refer to the Apyx Medical
Corporation website at www.ApyxMedical.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220127005178/en/
Investor Relations: ICR
Westwicke on behalf of Apyx Medical Corporation Mike Piccinino, CFA
investor.relations@apyxmedical.com
Apyx Medical (NASDAQ:APYX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Apyx Medical (NASDAQ:APYX)
Historical Stock Chart
From Apr 2023 to Apr 2024